Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells
- 31 October 2011
- journal article
- Published by Elsevier BV in Bone
- Vol. 49 (4), 710-716
- https://doi.org/10.1016/j.bone.2011.07.020
Abstract
No abstract availableKeywords
Funding Information
- Health Research Council of New Zealand
This publication has 32 references indexed in Scilit:
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Early tumor dissemination, but late metastasis: insights into tumor dormancyJCI Insight, 2010
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialThe Lancet Oncology, 2010
- Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivoJournal of Bone and Mineral Research, 2010
- Cancer micrometastasesNature Reviews Clinical Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate‐associated osteonecrosisBritish Journal of Haematology, 2009
- Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBritish Journal of Haematology, 2008